<DOC>
	<DOCNO>NCT00263679</DOCNO>
	<brief_summary>The aim study evaluate safety immunogenicity booster dose GSK Biological 's candidate Tdap vaccine contain 0.3 mg Al administer healthy school child adolescent ( 9-13 year age ) previously vaccinate five consecutive dos Pa-containing vaccine . The inclusion hepatitis A vaccine ( HavrixÂ® ) control vaccine enables study conduct double-blinded term immunogenicity safety assessment .</brief_summary>
	<brief_title>Assessment GSK Biologicals ' Tdap Candidate Vaccine Administered Booster ( 6th Dose ) Terms Immunogenicity Safety Children Adolescents Previously Vaccinated With Five Doses Acellular Pertussis-containing Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects previously enrol vaccinated GSK Biologicals ' study APV118 APV120 9 13 year age Use investigational nonregistered drug vaccine study vaccine within 30 day precede administration study vaccine , plan use study period . Chronic administration plan administration immunosuppressant immune modify drug within six month prior study vaccination plan administration study period Administration immunoglobulins and/or blood product within 3 month prior vaccination</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>